Free Newsletter
Amgen, J&J settle sales-discount lawsuit
Amgen agreed to pay $200 million to settle an antitrust lawsuit by Johnson & Johnson's Ortho Biotech unit, putting to rest 2½ years of legal wrangling over Amgen's sales of its oncology products Aranesp, Neupogen, and Neulasta. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
